Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Artivion, Inc.NYSE: AORT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital declines year over year
Q1 FY2026 change in working capital of $19.13M (cash outflow) fell 28.5% year over year, ahead of the -47.7% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Change in working capital amounted to 5.0% of revenue in FY2025, up 0.6 pp from a year earlier.
- Change in working capital grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -28.5% holds above the trailing-twelve-month pace of -47.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (22.16M) USD
- Year-over-year change
- -28.5%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.16M) | -28.5% |
| FY2024 | 2024-12-31 | (17.24M) | -6.5% |
| FY2023 | 2023-12-31 | (16.19M) | +37.6% |
| FY2022 | 2022-12-31 | (25.94M) | +22.0% |
| FY2021 | 2021-12-31 | (33.23M) | — |
Change in Working Capital vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 change in working capital of $14.53M is the 9th largest of the 11 companies compared; the peer median is $25.17M.
- Its year-over-year change of -47.7% is the 6th highest of 11, against a peer median of -42.3%.
- Change in working capital amounts to 3.2% of revenue for AORT, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $98.16M | +372.6% | +16.7% | 5.3% | |
| LTM Jun 2026 | $44.89M | +285.7% | +123.8% | 10.0% | |
| LTM Jun 2026 | $37.35M | -51.6% | — | 4.2% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $35.97M | -82.9% | -30.0% | 0.6% |
| LTM Mar 2026 | $25.41M | -33.0% | -12.0% | 7.9% | |
| LTM Jun 2026 | $24.92M | -262.0% | +120.1% | — | |
| LTM Jun 2026 | $18.25M | +166.2% | — | 1.2% | |
| LTM Sep 2026 | $16.48M | -53.7% | — | 0.6% | |
| LTM Mar 2026 | $14.53M | -47.7% | -5.1% | 3.2% | |
| LTM Mar 2026 | $14.37M | +64.7% | +70.9% | 29.7% | |
| LTM Jun 2026 | $6.14M | -116.8% | +33.5% | 0.4% | |
| Peer median (excluding AORT) | $25.17M | -42.3% | +33.5% | 4.2% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| Deferred Income Tax | (4.47M) | (1.72M) | (1.39M) | (1.51M) | 37K |
| Stock-Based Compensation | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M |
| Change in Working Capital | (33.23M) | (25.94M) | (16.19M) | (17.24M) | (22.16M) |
| Accounts Receivables | (11.56M) | (13.34M) | (4.05M) | (15.4M) | (7.27M) |
| Inventory | (18.38M) | (8.4M) | (14.36M) | (6.14M) | (15.28M) |
| Accounts Payables | (1.89M) | (1.96M) | 1.68M | 9.5M | 2.18M |
| Other Working Capital | (1.4M) | (2.23M) | 535K | (5.21M) | (1.8M) |
| Other Non-Cash Items | 15.26M | 6.91M | 29.6M | 15.9M | 3.64M |
| Operating Cash Flow | (2.59M) | (5.15M) | 18.83M | 22.24M | 38.13M |
| Capital Expenditures | (13.09M) | (10.72M) | (7.43M) | (11.19M) | (39.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 19M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (249K) | 0 | 6.93M | (17M) | (3M) |
| Investing Cash Flow | 5.66M | (10.72M) | (502K) | (28.19M) | (42.04M) |
| Debt Repayment | (3.09M) | (2.75M) | (2.77M) | (358K) | (2.46M) |
| Common Stock Issued | 0 | 0 | 0 | 5.73M | 13.07M |
| Common Stock Repurchased | (1.91M) | (1.8M) | (559K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.22M) | 2.91M | 4.2M | (3.17M) | 2.42M |
| Financing Cash Flow | (12.22M) | (1.64M) | 865K | 2.2M | 13.03M |
| Effect of Forex Changes | 2.2M | 1.85M | 401K | (1.73M) | 2.32M |
| Net Change in Cash | (6.95M) | (15.66M) | 19.59M | (5.48M) | 11.45M |
| Free Cash Flow | (15.68M) | (15.87M) | 11.4M | 11.05M | (911K) |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.